Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher : Cytiva strengthens support to diagnostics industry with new labs, services and supply chain enhancements

10/27/2020 | 03:01am EDT
  • Now offering Cytiva Diagnostic Services, new diagnostic test development and support service virtually or at new lab, for point-of-care diagnostic developers to increase speed to market of new tests.
  • Supply chain enhancements include increasing inventory, investing in plants and expanding number of partner organizations.

AMERSHAM, United Kingdom, Oct. 27, 2020 /CNW/ -- Cytiva launches new services for diagnostic developers and will establish new labs to meet the future needs of the industry. Cytiva Diagnostic Services will help developers bring point-of-care diagnostic tests to market quicker through infrastructure, expertise and consultation for point of care immunoassay development. A multi-million dollar investment will be used partly to expand chemistry labs in Cardiff, Wales as well as establishing design labs in Germany and China.

Cytiva has had a critical role working with diagnostic developers during the COVID-19 pandemic. In total, over 50 million people have been PCR tested using components or services from Cytiva. Diagnostic components, such as nitrocellulose membranes, are used in 18 immunoassay-based COVID-19 tests available today.

Investment in its molecular diagnostic component lab in Wales means more work with companies such as genedrive, a molecular diagnostics company. David Budd, CEO genedrive says, "Our R&D teams worked effectively together in combining their expertise, experience, and technologies to deliver innovative PCR Kits based on Cytiva's 'Ready-to-Go' formulations. The speed at which we were able to move together was facilitated by many previous years of cooperative working."

The new services will follow the same collaborative approach as Cytiva's work with Avacta. The companies are co-developing a rapid antigen test strip for COVID-19 to provide a result in minutes using patient saliva.

Alastair Smith, CEO of Avacta, comments: "Cytiva has been a key partner in developing a rapid coronavirus antigen test and we continue to work closely with them, and our manufacturing partners, to finalise the test in a format suitable for massively scaled-up manufacturing processes to meet the anticipated demand."

The new services will include training, test optimization expertise and contract development and can be hosted virtually or in person at Cytiva's new lab in Dassel, Germany. Another lab for diagnostics development work is being planned for China in 2021. These projects form part of Cytiva's 500 million USD investment over five years to expand manufacturing capacity.

Emmanuel Abate, Vice President, Genomics and Cellular Research at Cytiva, says: "We have seen a lot of new companies entering the field this year to address the challenges of the pandemic. As a diagnostic component provider with over 30 years' experience, we have a key role supporting the industry through the next series of challenges with our manufacturing and design expertise."

Join Cytiva's Diagnostics Virtual Summit
On Oct 28 Cytiva is hosting a thought-provoking and interactive virtual summit showcasing recently launched technologies, products and solutions supporting the development of diagnostics. Register here for the live event or access the playback (available for 12 months).

About Cytiva
Cytiva is a global life sciences leader with more than 7,000 associates across 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients.

Cision
View original content:http://www.prnewswire.com/news-releases/cytiva-strengthens-support-to-diagnostics-industry-with-new-labs-services-and-supply-chain-enhancements-301159514.html

SOURCE Cytiva

© Canada Newswire, source Canada Newswire English

All news about DANAHER CORPORATION
09/21DANAHER : Schedules Third Quarter 2021 Earnings Conference Call
PR
09/15DANAHER CORP /DE/ : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
09/14DANAHER : Keeps Quarterly Cash Dividend Unchanged at $0.21 a Share, Payable Oct. 29 to Sha..
MT
09/14DANAHER : Announces Quarterly Dividends
PR
09/14Danaher Corporation Approves Regular Quarterly Cash Dividend, Payable on October 29, 20..
CI
09/10DANAHER : Credit Suisse Raises Danaher's PT to $370 from $306, Notes Heightened Conviction..
MT
09/08DANAHER : RBC Raises Price Target on Danaher to $332 From $304 Ahead of Analyst Day, Maint..
MT
09/03DANAHER : Helping Customers Make Better Beer -- and Improve Sustainability
PU
09/01SCIEX : Presents Industry First Multi-Capillary System for CE-SDS, the BioPhase 8800 Syste..
BU
09/01SCIEX : Builds on Cadence of Innovation in Biopharma With Biologics Explorer
BU
More news
Analyst Recommendations on DANAHER CORPORATION
More recommendations
Financials (USD)
Sales 2021 28 673 M - -
Net income 2021 6 136 M - -
Net Debt 2021 14 651 M - -
P/E ratio 2021 39,2x
Yield 2021 0,27%
Capitalization 232 B 232 B -
EV / Sales 2021 8,59x
EV / Sales 2022 7,99x
Nbr of Employees 68 000
Free-Float 74,2%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Last Close Price 324,50 $
Average target price 325,11 $
Spread / Average Target 0,19%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos GutiÚrrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors